Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential (Q27688944)

7

Zygmunt Kazimierczuk

0 references

Giorgio Cozza

Giorgio Cozza

1

0 references

Lorenzo A Pinna

Lorenzo A Pinna

10

0 references

Andrzej Orzeszko

Andrzej Orzeszko

6

0 references

Stefania Sarno

Stefania Sarno

5

0 references

author name string

Cristina Girardi

2

0 references

Alessandro Ranchio

3

0 references

Graziano Lolli

4

0 references

Roberto Battistutta

Cellular and Molecular Life Sciences

8

0 references

publication date

August 2014

0 references

published in

0 references

volume

71

0 references

issue

16

0 references

page(s)

3173-85

0 references

cites work

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Kinase drug discovery--what's next in the field?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Selectively nonselective kinase inhibition: striking the right balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

The selectivity of inhibitors of protein kinase CK2: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

ATP site-directed inhibitors of protein kinase CK2: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Overview of the CCP4 suite and current developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Phasercrystallographic software

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Features and development of Coot

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

PHENIX: a comprehensive Python-based system for macromolecular structure solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Development and validation of a genetic algorithm for flexible docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Protein kinase CK2 phosphorylates and upregulates Akt/PKB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2').

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

For better or for worse: the role of Pim oncogenes in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Emergence of protein kinase CK2 as a key target in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Casein kinase 2α regulates multidrug resistance-associated protein 1 function via phosphorylation of Thr249.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Assessment of CK2 constitutive activity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-013-1552-5

Stereospecific synthesis by the sodium salt glycosylation method of halogeno benzimidazole 2'-deoxyribose analogues of the inhibitor of hnRNA synthesis, 5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole (DRB)

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24442476

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24442476

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24442476